Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.
- Menke MN Department of Ophthalmology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland. marcel.menke@ksa.ch.
- Framme C Department of Ophthalmology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland. framme.carsten@mh-hannover.de.
- Nelle M Department of Neonatology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland. mathias.nelle@insel.ch.
- Berger MR Department of Neonatology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland. markus.berger@insel.ch.
- Sturm V Department of Ophthalmology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland. veit.sturm@kssg.ch.
- Wolf S Department of Ophthalmology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland. sebastian.wolf@insel.ch.
- 2015-04-18
Published in:
- BMC ophthalmology. - 2015
Angiogenesis Inhibitors
Female
Gestational Age
Humans
Infant, Extremely Low Birth Weight
Infant, Newborn
Infant, Premature
Intravitreal Injections
Ranibizumab
Retinal Neovascularization
Retinopathy of Prematurity
Vascular Endothelial Growth Factor A
English
BACKGROUND
Treatment of retinopathy of prematurity (ROP) stage 3 plus with bevacizumab is still very controversial. We report the outcome of 6 eyes of 4 premature infants with ROP stage 3 plus disease treated with ranibizumab monotherapy.
METHODS
Six eyes of 4 premature infants with threshold ROP 3 plus disease in zone II, were treated with one intravitreal injection of 0.03 ml ranibizumab. No prior laser or other intravitreal therapy was done. Fundus examination was performed prior to the intervention and at each follow-up visit. Changes in various mean vital parameters one week post intervention compared to one week pre-intervention were assessed.
RESULTS
The gestational age (GA) of patient 1, 2, 3, and 4 at birth was 24 5/7, 24 5/7, 24 4/7, and 26 1/7 weeks, respectively. The birth weight was 500 grams, 450 grams, 665 grams, and 745 grams, respectively. The GA at the date of treatment ranged from 34 3/7 to 38 6/7 weeks. In one infant, upper air way infection was observed 2 days post injection of the second eye. Three eyes required paracentesis to reduce the intraocular pressure after injection and to restore central artery perfusion. After six months, all eyes showed complete retinal vascularisation without any signs of disease recurrence.
CONCLUSIONS
Treatment of ROP 3 plus disease with intravitreal ranibizumab was effective in all cases and should be considered for treatment. One infant developed an upper air way infection suspicious for nasopharyngitis, which might be a possible side effect of ranibizumab. Another frequent complication was intraocular pressure rise after injection. More patients with longer follow-up duration are mandatory to confirm the safety and efficacy of this treatment.
TRIAL REGISTRATION NUMBER
NCT02164604; Date of registration: 13.06.2014.
Treatment of retinopathy of prematurity (ROP) stage 3 plus with bevacizumab is still very controversial. We report the outcome of 6 eyes of 4 premature infants with ROP stage 3 plus disease treated with ranibizumab monotherapy.
METHODS
Six eyes of 4 premature infants with threshold ROP 3 plus disease in zone II, were treated with one intravitreal injection of 0.03 ml ranibizumab. No prior laser or other intravitreal therapy was done. Fundus examination was performed prior to the intervention and at each follow-up visit. Changes in various mean vital parameters one week post intervention compared to one week pre-intervention were assessed.
RESULTS
The gestational age (GA) of patient 1, 2, 3, and 4 at birth was 24 5/7, 24 5/7, 24 4/7, and 26 1/7 weeks, respectively. The birth weight was 500 grams, 450 grams, 665 grams, and 745 grams, respectively. The GA at the date of treatment ranged from 34 3/7 to 38 6/7 weeks. In one infant, upper air way infection was observed 2 days post injection of the second eye. Three eyes required paracentesis to reduce the intraocular pressure after injection and to restore central artery perfusion. After six months, all eyes showed complete retinal vascularisation without any signs of disease recurrence.
CONCLUSIONS
Treatment of ROP 3 plus disease with intravitreal ranibizumab was effective in all cases and should be considered for treatment. One infant developed an upper air way infection suspicious for nasopharyngitis, which might be a possible side effect of ranibizumab. Another frequent complication was intraocular pressure rise after injection. More patients with longer follow-up duration are mandatory to confirm the safety and efficacy of this treatment.
TRIAL REGISTRATION NUMBER
NCT02164604; Date of registration: 13.06.2014.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1186/s12886-015-0001-7
- PMID 25886603
- Persistent URL
- https://sonar.ch/global/documents/278468
Statistics
Document views: 25
File downloads:
- Full-text: 0